Positron emission tomography diagnosis of Alzheimer's disease.
Positron emission tomography (PET) imaging of [18F]-2-fluoro-2-deoxy-D-glucose (FDG) is accurate in the early detection of Alzheimer's disease (AD) and in the differentiation of AD from the other causes of dementia. FDG-PET imaging is available widely and performed easily. Different patterns of abnormality with the various causes of dementia are well described. Semiquantitative methods of image interpretation are available. Medicare covers FDG-PET imaging for the narrow indication of differentiation of possible AD from frontotemporal dementia.
Coleman
R Edward
RE
Department of Radiology, Duke University Medical Center, Box 3949, Durham, NC 27710, USA. colem010@mc.duke.edu
D000544:Alzheimer Disease / Q000175:diagnosis* / Q000191:economics; D001921:Brain / Q000000981:diagnostic imaging*; D003937:Diagnosis, Differential; D019788:Fluorodeoxyglucose F18; D006801:Humans; D049268:Positron-Emission Tomography / Q000191:economics / Q000379:methods*; D019275:Radiopharmaceuticals
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18